About Affinia Therapeutics
Affinia Therapeutics is a private company based in Waltham, Massachusetts. It has reported $170,141,232 raised in four offerings on Form D since November 2019. Its chief executive is Rick Modi.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2025 | Oct 14, 2025 | $13,268,335of $45.0M target | 20 | $663K | EquityRule 506(b) | Form D ↗ |
| Apr 20, 2021 | May 6, 2021 | $109,999,955fully sold | 22 | $4.9M | EquityRule 506(b) | Form D ↗ |
| Mar 12, 2020 | Mar 27, 2020 | $38,522,942of $68.5M target | 16 | $2.4M | EquityRule 506(b) | Form D ↗ |
| Oct 22, 2019 | Nov 5, 2019 | $8,350,000fully sold | 14 | $596K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $170,141,232 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Affinia Therapeutics's Form D filed Oct 14, 2025.
Earlier filings also listed Robert Aboud (executive officer, last listed May 2021), Rob May (executive officer, last listed May 2021), Petra Kaufmann (executive officer, last listed May 2021), Paula Cobb (executive officer, last listed May 2021), Laura Richman (executive officer, last listed May 2021), Elliot Sigal (director, last listed May 2021), Charles Albright (executive officer, last listed May 2021) and Caroline Stout (director, last listed May 2021).